All In Biotech

NDA 200890 · Sandoz

Isopto Carpine

Pilocarpine Hydrochloride · Ophthalmic

Priority review

Last checked: Nov 19, 2026Latest source record: Feb 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jun 22, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

21 Phase 3, 2 recruiting

FAERS reports

1,211

642 serious, 34 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 19, 2020.

Pilocarpine hydrochloride ophthalmic solution is indicated for the: Pilocarpine hydrochloride ophthalmic solution is a muscarinic cholinergic agonist indicated for: • The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1.1 ) • The management of acute angle-closure glaucoma. ( 1.2 ) • The prevention of postoperative elevated IOP associated with laser surgery. ( 1.3 ) • The induction of miosis. ( 1.4 ) 1.1 Reduction of Elevated Intraocular Pressure (IOP) in Patients With Open-Angle Glaucoma or Ocular Hypertension . 1.2 Management of Acute Angle-Closure Glaucoma . 1.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery . 1.4 Induction of Miosis .

Mechanism: Pilocarpine hydrochloride is a direct acting cholinergic parasympathomimetic agent which acts through direct stimulation of muscarinic receptors and smooth muscle such as the iris and secretory glands. Pilocarpine contracts the ciliary muscle, causing increased tension on the scleral spur and opening of the trabecular meshwork spaces to facilitate outflow of aqueous humor. Outflow resistance is reduced, lowering IOP. Pilocarpine also produces miosis through contraction of the iris sphincter muscle. Miosis relieves appositional angle narrowing and closure, which lowers IOP in certain types of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ISOPTO CARPINE · PILOCARPINE HYDROCHLORIDE 4% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
  • ISOPTO CARPINE · PILOCARPINE HYDROCHLORIDE 1% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
  • ISOPTO CARPINE · PILOCARPINE HYDROCHLORIDE 2% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Pilocarpine" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective132
  • headache97
  • fatigue96
  • pain96
  • eye pain90
  • dyspnoea85
  • nausea77
  • dizziness75
  • diarrhoea74
  • cough68
  • fall67
  • off label use67

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200520
20066
20075
200815
200935
201043
20118
201214
201318
201415
201516
20167
201729
201840
201977
202093
202168
2022119
2023107
2024140
2025184
2026135

Recalls

1 FDA enforcement reports for this application.

  • Mar 22, 2017 · Class III · Terminated

    Failed Impurities/Degradation Specifications.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 408 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.